Immunization

Providing immunization coadministration and assisting with insurance coverage are strategies to improve access.

Understanding preventive care reduces the risk of illnesses and decreases future costs.

Differentiating between the 3 available options can help identify which is best for individual patients.

Proper timing and vaccine selection are crucial for optimal immune responses.

With new guidance coming for the 2024-2025 season, pharmacists must stay up to date with current vaccine recommendations.

A strong recommendation from trusted health care professionals can make a difference.

Pharmacists have become the driving force behind immunizations in the US.

Investigators found that the risk of long COVID decreased over the course of the pandemic.

Many ways exist to best serve communities and the bottom line beyond vaccine ordering and increased staffing.

Pharmacists’ awareness of respiratory syncytial virus and their role in educating about the vaccine have grown dramatically.

RSVpreF is currently the only FDA-approved RSV vaccine for pregnant individuals.

The ACIP recommendations are designed to improve access to RSV vaccination, emphasizing the need to get vaccinated.

The committee, after being presented evidence by the working group, recommended the vaccine for adults aged 65 and older and those 19 or older who have current recommendations to receive a pneumococcal vaccine.

Staying updated on travel vaccines and applying sunscreen are examples of summer health counseling tips

Pharmacies can position themselves as leaders in immunization services.

V116 (Capvaxive; Merck) elicited higher immune responses than the comparator for the serotypes that are unique to the vaccine, according to studies submitted to the FDA.

The SCDM model demands more than the traditional roles assigned to pharmacists, requiring an enhanced level of patient engagement, medical knowledge, and legal authority to implement effectively

The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.

Serotypes associated with V116 (Merck & Co. Inc.) had higher clinical and economic burden for individuals with invasive pneumococcal disease.

A single dose of the vaccine showed long-lasting protection against RSV-associated lower respiratory tract disease in older adults.

The immunizing technicians stated they had greater job satisfaction and had a greater sense of being valuable pharmacy members

This is Moderna's second mRNA vaccine approval and the first mRNA vaccine approved for an indication other than COVID-19.

Pediatric patients with rheumatic disease, such as systemic lupus erythematosus, mixed connective tissue disease, juvenile dermatomyositis, and systemic vasculitis are at an increased risk of serious infection.

As Summer Approaches, Many Will Be Planning Vacations and Trips Abroad

This is the first approval of an EB virus-related mRNA therapeutic cancer vaccine and is a landmark achievement in future research on cancer treatment.

Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.

Additionally, undocumented Latinx patients were also more likely to have at least 1 prior COVID-19 infection.

Notable contributions from female leaders in the pharmaceutical industry demonstrate the exceptional competence of women in vaccine innovation.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.